Yunnan Biovalley Pharmaceutical Co (BJSE:833266) LT-Debt-to-Total-Asset : 0.03 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Yunnan Biovalley Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Yunnan Biovalley Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.03.

Yunnan Biovalley Pharmaceutical Co's long-term debt to total assets ratio declined from Sep. 2023 (0.05) to Sep. 2024 (0.03). It may suggest that Yunnan Biovalley Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Yunnan Biovalley Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Yunnan Biovalley Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yunnan Biovalley Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Yunnan Biovalley Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.07

0.06

0.04

Yunnan Biovalley Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.04	0.04	0.03	0.03

Yunnan Biovalley Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Yunnan Biovalley Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	53.862	/	1235.702
	=	0.04

Yunnan Biovalley Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	38.315	/	1214.099
	=	0.03

Yunnan Biovalley Pharmaceutical Co (BJSE:833266) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Yunnan Biovalley Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Yunnan Biovalley Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Yunnan Biovalley Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yunnan Biovalley Pharmaceutical Co Ltd (BJSE:833266) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 999 Biological Valley Street, Majinpu New District, High-tech Zone, Yunnan Province, Kunming City, CHN, 650500

Website

Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.

Yunnan Biovalley Pharmaceutical Co Headlines

No Headlines